Valeant Sells "Female Viagra" Developer Sprout Pharma Back to Its Shareholders

Valeant Pharmaceuticals International said today it has agreed to sell its Sprout Pharmaceuticals subsidiary to its former shareholders, more than two years after the seller acquired the developer of female sexual dysfunction drug Addyi® (flibanserin) for $1 billion plus a share of future profits tied to milestones.In return for the sell-off, Valeant said, it will collect a 6% royalty on global sales of Addyi starting 18 months from the signing of the sale agreement, as well as issue a $25 m